Cited by 1,730Renal cell carcinoma treatmentEar and Head TumorsCancer, Hypoxia, and Metabolism

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Mutations of the VHL tumour suppressor gene in renal carcinoma

Gnarra, J.R., Tory, K., Weng, Y., Schmidt, L., Wei, M.H., Li, H., Latif, F., Liu, S., Chen, F., Duh, F.-M., Lubensky, I., Duan, D.R., Florence, C., Pozzatti, R., Walther, M. M., Bander, N.H., Grossman, H.B., Brauch, H., Pomer, S., Brooks, J.D., Isaacs, W.B., Lerman, M.I., Zbar, B., Linehan, W.M.·1994·Nature Genetics

DOI 10.1038/ng0594-85

Open this paper in CoChat — free account

Abstract

Multiple, bilateral renal carcinomas are a frequent occurrence in von Hippel-Lindau (VHL) disease. To elucidate the aetiological role of the VHL gene in human kidney tumorigenesis, localized and advanced tumours from 110 patients with sporadic renal carcinoma were analysed for VHL mutations and loss of heterozygosity (LOH). VHL mutations were identified in 57% of clear cell renal carcinomas analysed and LOH was observed in 98% of those samples. Moreover, VHL was mutated and lost in a renal tumour from a patient with familial renal carcinoma carrying the constitutional translocation, t(3;8)(p14;q24). The identification of VHL mutations in a majority of localized and advanced sporadic renal carcinomas and in a second form of hereditary renal carcinoma indicates that the VHL gene plays a critical part in the origin of this malignancy.

Integrity signals

Registry

Crossref · 10.1038/ng0594-85

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Identification of the von Hippel-Lindau Disease Tumor Suppressor Gene
Latif, F., Tory, K., Gnarra, J. R., Yao, M., Duh, F.-M. C., Orcutt, M. L., Stackhouse, T. M., Kuzmin, I., Modi, W. S., Geil, L., et al. (1993) · Science · doi:10.1126/science.8493574 · Cited by 2,971
Self-citation
The Results of Radical Nephrectomy for Renal Cell Carcinoma
Robson, C. J., Churchill, B. M., & Anderson, W. D. (1969) · The Journal of Urology · doi:10.1016/s0022-5347(17)62331-0 · Cited by 1,303
Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC
Donis-Keller, H., Dou, S., Chi, D., Carlson, K. M., Toshima, K., Lairmore, T. C., Howe, J. R., Moley, J. F., Goodfellow, P. J., & Wells, S. A. (1993) · Human Molecular Genetics · doi:10.1093/hmg/2.7.851 · Cited by 1,298
Hereditary cancer, oncogenes, and antioncogenes.
Knudson, A. G. (1985) · PubMed · Cited by 1,218
The Results of Radical Nephrectomy for Renal Cell Carcinoma
Robson, C. J., Churchill, B. M., & Anderson, W. D. (2016) · The Journal of Urology · doi:10.1016/j.juro.2016.10.095 · Cited by 1,160
A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma
Hofstra, R. M. W., Landsvater, R. M., Ceccherini, I., Stulp, R. P., Stelwagen, T., Luo, Y., Pasini, B., Höppener, J. W. M., van Amstel, H. K. P., Romeo, G., et al. (1994) · Nature · doi:10.1038/367375a0 · Cited by 1,143
Diseases of the kidney
Strauss, M. B., & Welt, L. G. (1963) · Little, Brown eBooks · Cited by 823
Mutations of the RET proto-oncogene in Hirschsprung's disease
Edery, P., Lyonnet, S., Mulligan, L. M., Pelet, A., Dow, E., Abel, L., Holder, S., Nihoul‐Feketé, C., Ponder, B. A. J., & Münnich, A. (1994) · Nature · doi:10.1038/367378a0 · Cited by 746
Point mutations affecting the tyrosine kinase domain of the RET proto-oncogene in Hirschsprung's disease
Romeo, G., Ronchetto, P., Luo, Y., Barone, V., Seri, M., Ceccherini, I., Pasini, B., Bocciardi, R., Lerone, M., Kääriäinen, H., et al. (1994) · Nature · doi:10.1038/367377a0 · Cited by 698
Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC
Mulligan, L. M., Eng, C., Healey, C. S., Clayton, D. G., Kwok, J. B., Gardner, E., Ponder, M. A., Frilling, A., Jackson, C. E., Lehnert, H., et al. (1994) · Nature Genetics · doi:10.1038/ng0194-70 · Cited by 643

Show all 29 references

Research works printed but not linked: 1

Glenn, G.M., Choyke, P.L., Zbar, B. & Linehan, W.M. von Hippel-Lindau disease: clinical review and molecular genetics. Problems Urol. 4, 312–330 (1990).

Sorted by citations

Items 601–700 of 1,002

Tumor suppressor protein VHL is induced at high cell density and mediates contact inhibition of cell growth
Baba, M., Hirai, S.-I., Kawakami, S., Kishida, T., Sakai, N., Kaneko, S., Yao, M., Shuin, T., Kubota, Y., Hosaka, M., et al. (2001) · Oncogene · doi:10.1038/sj.onc.1204397 · Cited by 48
Requirement for the von Hippel-Lindau tumor suppressor gene for functional epidermal growth factor receptor blockade by monoclonal antibody C225 in renal cell carcinoma.
Perera, A. D., Kleymenova, E., & Walker, C. L. (2000) · PubMed · Cited by 48
A familial case of renal cell carcinoma and a t(2;3) chromosome translocation
Koolen, M. I., van der Meyden, A. P. M., Bodmer, D., Eleveld, M. J., van der Looij, E., Brunner, H. G., Smits, A., van den Berg, E., Smeets, D., & van Kessel, A. G. (1998) · Kidney International · doi:10.1046/j.1523-1755.1998.00762.x · Cited by 48
Von Hippel-Lindau disease gene deletion detected in microdissected sporadic human colon carcinoma specimens
Zhuang, Z., Emmert‐Buck, M. R., Roth, M. J., Gnarra, J. R., Linehan, W. M., Liotta, L. A., & Lubensky, I. A. (1996) · Human Pathology · doi:10.1016/s0046-8177(96)90368-8 · Cited by 48
Self-citation
Biomarkers in renal cell carcinoma
McGuire, B. B., & Fitzpatrick, J. M. (2009) · Current Opinion in Urology · doi:10.1097/mou.0b013e32832f0c68 · Cited by 47
Hypoxia-Induced SUMOylation of E3 Ligase HAF Determines Specific Activation of HIF2 in Clear-Cell Renal Cell Carcinoma
Koh, M. Y., Nguyen, V. H., Lemos, R., Darnay, B. G., Kiriakova, G. M., Abdelmelek, M. F., Ho, T. H., Karam, J. A., Monzon, F. A., Jonasch, E. W., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2190 · Cited by 48
Methylation level of the RASSF1A promoter is an independent prognostic factor for clear-cell renal cell carcinoma
Kawai, Y., Sakano, S., Suehiro, Y., Okada, T., Korenaga, Y., Hara, T., Naito, K., Matsuyama, H., & Hinoda, Y. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp577 · Cited by 47
Sustained nontumorigenic phenotype correlates with a largely stable chromosome content during long-term culture of the human keratinocyte line HaCaT
Boukamp, P., Popp, S., Altmeyer, S., Hülsen, A., Fasching, C. L., Cremer, T. J., & Fusenig, N. E. (1997) · Genes Chromosomes and Cancer · doi:10.1002/(sici)1098-2264(199708)19:4 · Cited by 146
The GNAS1 T393C Polymorphism Predicts Survival in Patients with Clear Cell Renal Cell Carcinoma
Frey, U. H., Lümmen, G., Jäger, T., Jöckel, K., Schmid, K. W., Rubben, H., Müller, N., Siffert, W., & Eisenhardt, A. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1722 · Cited by 47
Familial adult renal neoplasia
Takahashi, M., Kahnoski, R. J., Gross, D., Nicol, D. L., & Teh, B. T. (2002) · Journal of Medical Genetics · doi:10.1136/jmg.39.1.1 · Cited by 47
THE GENETIC BASIS OF BREAST CANCER AND ITS CLINICAL IMPLICATIONS
Bennett, I., Gattas, M. R., & Teh, B. T. (1999) · Australian and New Zealand Journal of Surgery · doi:10.1046/j.1440-1622.1999.01515.x · Cited by 47
CircME1 promotes aerobic glycolysis and sunitinib resistance of clear cell renal cell carcinoma through cis-regulation of ME1
Zhang, M.-X., Wang, J., Mo, C., Mao, X., Feng, Z., Li, J., Lin, H., Song, H., Xu, Q., Wang, Y., et al. (2022) · Oncogene · doi:10.1038/s41388-022-02386-8 · Cited by 46
The Molecular Biology of Renal Cell Carcinoma
O’Keefe, S. J., Nathanson, K. L., & Rathmell, W. K. (2013) · Seminars in Oncology · doi:10.1053/j.seminoncol.2013.05.006 · Cited by 48
Monoclonal antibody G250 targeting CA IX: Binding specificity, internalization and therapeutic effects in a non-renal cancer model
Zaťovičová, M., Jelenska, L., Hulı́ková, A., Ditte, P., Ditte, Z., Csáderová, L., Švastová, E., Schmalix, W. A., Böttger, V., Bevan, P., et al. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2658 · Cited by 46
VHLdb: A database of von Hippel-Lindau protein interactors and mutations
Tabaro, F., Minervini, G., Sundus, F., Quaglia, F., Leonardi, E., Piovesan, D., & Tosatto, S. C. E. (2016) · Scientific Reports · doi:10.1038/srep31128 · Cited by 46
Determination of Angptl4 mRNA as a Diagnostic Marker of Primary and Metastatic Clear Cell Renal-Cell Carcinoma
Verine, J., Lehmann‐Che, J., Soliman, H. R., Feugeas, J., Vidal, J., Mongiat-Artus, P., Belhadj, S., Philippe, J., Lesage, M., Evelyne, W.-D., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010421 · Cited by 46
Prognostic Factors in Renal Cell Carcinoma
Shuch, B., LAM, J., Belldegrun, A. S., & Figlin, R. A. (2006) · Seminars in Oncology · doi:10.1053/j.seminoncol.2006.06.006 · Cited by 46
Coexpression of transforming growth factor-alpha and épidermal growth factor receptor in capillary hemangioblastomas of the central nervous system.
Reifenberger, G., REIFENBERGER, J., Bilzer, T., Wechsler, W., & Collins, V. P. (1995) · Europe PMC (PubMed Central) · Cited by 46
Parathyroid hormone-related protein in human renal cell carcinoma
Sourbier, C., & Massfelder, T. (2005) · Cancer Letters · doi:10.1016/j.canlet.2005.08.020 · Cited by 45
Expression and regulatory effects on cancer cell behavior of NELL1 and NELL2 in human renal cell carcinoma
Nakamura, R., Oyama, T., Tajiri, R., Mizokami, A., Namiki, M., Nakamoto, M., & Ooi, A. (2015) · Cancer Science · doi:10.1111/cas.12649 · Cited by 45
Monocarboxylate transporter 1 and monocarboxylate transporter 4 in cancer-endothelial co-culturing microenvironments promote proliferation, migration, and invasion of renal cancer cells
Guo, C., Huang, T., Wang, Q., Li, H., Khanal, A., Kang, E.-H., Zhang, W., Niu, H., Dong, Z., & Cao, Y. (2019) · Cancer Cell International · doi:10.1186/s12935-019-0889-8 · Cited by 46
Self-citation
Isolation and characterization of the novel gene, TU3A, in a commonly deleted region on 3p14.3→p14.2 in renal cell carcinoma
Yamato, T., Orikasa, K., Fukushige, S.-I., Orikasa, S., & Horii, A. (1999) · Cytogenetic and Genome Research · doi:10.1159/000015452 · Cited by 45
Association of a novel constitutional translocation t(1q;3q) with familial renal cell carcinoma
Kanayama, H., Lui, W., Takahashi, M., Naroda, T., Kedra, D., Wong, F. K., Kuroki, Y., Nakahori, Y., Larsson, C., Kagawa, S., et al. (2001) · Journal of Medical Genetics · doi:10.1136/jmg.38.3.165 · Cited by 45
Expression of von Hippel–Lindau Protein in Normal and Pathological Human Tissues
Sakashita, N., Takeya, M., Kishida, T., Stackhouse, T. M., Zbar, B., & Takahashi, K. (1999) · The Histochemical Journal · doi:10.1023/a:1003554712386 · Cited by 45
Self-citation
The genetic basis of renal cell carcinoma
Pavlovich, C. P., Schmidt, L. S., & Phillips, J. L. (2003) · Urologic Clinics of North America · doi:10.1016/s0094-0143(03)00023-5 · Cited by 46
Self-citation
PI3Kβ Inhibitor TGX221 Selectively Inhibits Renal Cell Carcinoma Cells with Both VHL and SETD2 mutations and Links Multiple Pathways
Feng, C., Sun, Y., Ding, G., Wu, Z., Jiang, H., Wang, L., Ding, Q., & Wen, H. (2015) · Scientific Reports · doi:10.1038/srep09465 · Cited by 45
The Genetic Basis of Pheochromocytoma and Paraganglioma: Implications for Management
Shuch, B. M., Ricketts, C. J., Metwalli, A. R., Pacák, K., & Linehan, W. M. (2014) · Urology · doi:10.1016/j.urology.2014.01.007 · Cited by 44
Self-citation
Kinase targets in renal-cell carcinomas: reassessing the old and discovering the new
Furge, K. A., MacKeigan, J. P., & Teh, B. T. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70380-8 · Cited by 44
HIF1α Expression under Normoxia in Prostate Cancer— Which Pathways to Target?
Ranasinghe, W. K. B., Baldwin, G. S., Bolton, D. M., Shulkes, A., Ischia, J. J., & Patel, O. (2014) · The Journal of Urology · doi:10.1016/j.juro.2014.10.085 · Cited by 47
Somatic point mutation of the wild-type allele detected in tumors of patients with VHL germline deletion
Vortmeyer, A. O., Huang, S. C., Pack, S., Koch, C. A., Lubensky, I. A., Oldfield, E. H., & Zhuang, Z. (2002) · Oncogene · doi:10.1038/sj.onc.1205121 · Cited by 44
Self-citation
New treatment approaches in renal cell carcinoma
Facchini, G., Perri, F., Caraglia, M., Pisano, C., Striano, S., Marra, L., Fiore, F., Aprea, P., Pignata, S., & Iaffaioli, R. V. (2009) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e32833123d4 · Cited by 44
Analysis of the TSC1and TSC2genes in sporadic renal cell carcinomas
Parry, L., Maynard, J., Patel, A. S., Clifford, S. C., Morrissey, C. O., Maher, E. R., Cheadle, J. P., & Sampson, J. R. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.2072 · Cited by 44
Molecular Genetics of Sporadic and Familial Renal Cell Carcinoma
Linehan, W. M. (2000) · doi:10.1007/978-1-4613-1101-0_3 · Cited by 44
Self-citation
Role of epidermal-growth-factor receptor in tumor progression in transformed human mammary epithelial cells
Ma, L., Gauvillé, C., Berthois, Y., Degeorges, A., Millot, G., Martin, P., & Calvo, F. M. (1998) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19980925)78:1 · Cited by 28
Self-citation
Physical and functional mapping of a tumor suppressor locus for renal cell carcinoma within chromosome 3p12.
Lott, S. T., Lovell, M., Naylor, S. L., & Killary, A. M. (1998) · PubMed · Cited by 44
Application of Molecular Diagnostic Techniques to Renal Epithelial Neoplasms
Jones, T. D., Eble, J. N., & Liang Cheng, C. (2005) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2005.01.011 · Cited by 43
Analysis of Germline Variants in CDH1, IGFBP3, MMP1, MMP3, STK15 and VEGF in Familial and Sporadic Renal Cell Carcinoma
Ricketts, C. J., Zeegers, M. P., Lubiński, J., & Maher, E. R. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006037 · Cited by 43
Neoplasms of the Kidney
MacLennan, G. T., & Liang Cheng, C. (2016) · Springer eBooks · doi:10.1007/978-3-319-23380-2_35 · Cited by 43
BMI, irAE, and gene expression signatures associate with resistance to immune-checkpoint inhibition and outcomes in renal cell carcinoma
Labadie, B. W., Liu, P., Bao, R., Crist, M., Fernandes, R., Ferreira, L., Graupner, S., Poklepovic, A. S., Durán, I., Vareki, S. M., et al. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-02144-7 · Cited by 43
PRDM16 suppresses HIF-targeted gene expression in kidney cancer
Kundu, A., Nam, H., Shelar, S. B., Chandrashekar, D. S., Brinkley, G. J., Karki, S., Mitchell, T., Livi, C. B., Buckhaults, P., Kirkman, R. L., et al. (2020) · The Journal of Experimental Medicine · doi:10.1084/jem.20191005 · Cited by 43
Novel homozygous VHL mutation in exon 2 is associated with congenital polycythemia but not with cancer
Lanikova, L., Lorenzo, F., Yang, C., Vankayalapati, H., Drachtman, R. A., Divoký, V., & Prchal, J. T. (2013) · Blood · doi:10.1182/blood-2012-11-469296 · Cited by 45
Adiposity and Age are Statistically Related to EnhancedRASSF1ATumor Suppressor Gene Promoter Methylation in Normal Autopsy Kidney Tissue
Peters, I., Vaske, B., Albrecht, K., Kuczyk, M. A., Udo Jonas, A., & Serth, J. (2007) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-07-0203 · Cited by 43
Molecular markers for predicting prognosis of renal cell carcinoma
Nogueira, M. A., & Kim, H. L. (2007) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2007.03.028 · Cited by 45
Biological Aspects and Binding Strategies of Vascular Endothelial Growth Factor in Renal Cell Carcinoma
Rini, B. I., & Rathmell, W. K. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2110 · Cited by 46
Five new cases of juvenile renal cell carcinoma with translocations involving Xp11.2
Pérot, C., Boccon-Gibod, L. A., Bouvier, R., Doz, F., Fournet, J., Fréneaux, P., Vieillefond, A., & Couturier, J. (2003) · Cancer Genetics and Cytogenetics · doi:10.1016/s0165-4608(02)00851-8 · Cited by 43
Gene targeting in kidney development
Kreidberg, J. A. (1996) · Medical and Pediatric Oncology · doi:10.1002/(sici)1096-911x(199611)27:5 · Cited by 25
Ran-mediated Nuclear Export of the von Hippel-Lindau Tumor Suppressor Protein Occurs Independently of Its Assembly with Cullin-2
Groulx, I., Bonicalzi, M.-E., & Lee, S. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.12.8991 · Cited by 43
Regulation of the urokinase-type plasminogen activator system by the von Hippel-Lindau tumor suppressor gene.
Los, M., Zeamari, S., Foekens, J. A., Gebbink, M. F. B. G., & Voest, E. E. (1999) · PubMed · Cited by 43
Repeat partial nephrectomy
Shuch, B. M., Linehan, W. M., & Bratslavsky, G. (2011) · Current Opinion in Urology · doi:10.1097/mou.0b013e32834964ea · Cited by 42
Self-citation
Inverse Association between Programmed Death Ligand 1 and Genes in the VEGF Pathway in Primary Clear Cell Renal Cell Carcinoma
Joseph, R. W., Parasramka, M. A., Eckel‐Passow, J. E., Serie, D., Wu, K. J., Jiang, L., Kalari, K. R., Thompson, R. H., Ho, T. H., Castle, E. P., et al. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0042 · Cited by 42
Validation of the type 1 insulin-like growth factor receptor as a therapeutic target in renal cancer
Yuen, J. S. P., Akkaya, E., Wang, Y., Takiguchi, M., Peak, S., Sullivan, M., Protheroe, A. S., & Macaulay, V. M. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0101 · Cited by 42
Carbonic anhydrase IX and renal cell carcinoma: prognosis, response to systemic therapy, and future vaccine strategies
Shuch, B. M., Li, Z., & Belldegrun, A. S. (2008) · British Journal of Urology · doi:10.1111/j.1464-410x.2008.07645.x · Cited by 42
The oncogenic role of MUC12 in RCC progression depends on c‐Jun/TGF‐β signalling
Gao, S., Yin, R. M., Zhang, L., Wang, S., Chen, J., Wu, X., Yue, C., Zuo, L., & Tang, M. M. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15515 · Cited by 42
Evolution of VHL tumourigenesis in nerve root tissue
Vortmeyer, A., Tran, M. G. B., Zeng, W., Gläsker, S., Riley, C., Tsokos, M., Ikejiri, B. L., Merrill, M., Raffeld, M. A., Zhuang, Z., et al. (2006) · The Journal of Pathology · doi:10.1002/path.2062 · Cited by 42
Endolymphatic sac tumor (aggressive papillary tumor of middle ear and temporal bone): sine qua non radiology-pathology and the University of Texas MD Anderson Cancer Center experience
Bell, D., Gidley, P. W., Levine, N. B., & Fuller, G. N. (2010) · Annals of Diagnostic Pathology · doi:10.1016/j.anndiagpath.2010.08.009 · Cited by 42
The von Hippel-Lindau gene
Clark, P. E., & Cookson, M. S. (2008) · Cancer · doi:10.1002/cncr.23645 · Cited by 43
Expression of HGF/SF and Met protein is associated with genetic alterations of VHL gene in primary renal cell carcinomas
Oh, R. R., Park, J. Y., Lee, J. H., Shin, M. S., Kim, H. S., Lee, S., Kim, Y. S., Lee, S. H., Lee, S. N., Yang, Y. M., et al. (2002) · Apmis · doi:10.1034/j.1600-0463.2002.100305.x · Cited by 42
A Phase II Clinical Trial of Ixabepilone (Ixempra; BMS-247550; NSC 710428), an Epothilone B Analog, in Patients with Metastatic Renal Cell Carcinoma
Huang, H., Menefee, M. E., Edgerly, M., Zhuang, S. H., Kotz, H. L., Poruchynsky, M. S., Huff, L. M., Bates, S. E., & Fojo, T. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0379 · Cited by 42
Tumor cell invasion of von Hippel Lindau renal cell carcinoma cells is mediated by membrane type-1 matrix metalloproteinase.
Petrella, B. L., & Brinckerhoff, C. (2006) · Molecular Cancer · doi:10.1186/1476-4598-5-66 · Cited by 42
von Hippel-Lindau Disease Gene Alterations Associated With Endolymphatic Sac Tumor
Vortmeyer, A. O., Pack, S., Zhuang, Z., Choo, D. I., & Oldfield, E. H. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.13.970-a · Cited by 42
The genetic basis of cancer of kidney cancer: implications for gene‐specific clinical management
Linehan, W. M., Grubb, R. L., Coleman, J., Zbar, B., & Walther, M. M. (2005) · British Journal of Urology · doi:10.1111/j.1464-410x.2005.05189.x · Cited by 43
Self-citation
Allelic Loss at the Tuberous Sclerosis (Tsc2) Gene Locus in Spontaneous Uterine Leiomyosarcomas and Pituitary Adenomas in the Eker Rat Model
Kubo, Y., Kikuchi, Y., Mitani, H., Kobayashi, E., Kobayashi, T., & Hino, O. (1995) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1995.tb03092.x · Cited by 42
A Pilot Study of Antiangiogenic Therapy with Bevacizumab and Thalidomide in Patients with Metastatic Renal Cell Carcinoma
Elaraj, D. M., White, D. E., Steinberg, S. M., Haworth, L. R., Rosenberg, S. A., & Yang, J. C. (2004) · Journal of Immunotherapy · doi:10.1097/00002371-200407000-00001 · Cited by 42
TANK-binding kinase 1 (TBK1): An emerging therapeutic target for drug discovery
Xiang, S., Song, S., Tang, H., Smaill, J. B., Wang, A., Xie, H., & Lu, X. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.05.016 · Cited by 41
All along the watchtower: Is the cilium a tumor suppressor organelle?
Mans, D. A., Voest, E. E., & Giles, R. H. (2008) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2008.02.002 · Cited by 43
A pilot clinical trial testing mutant von Hippel-Lindau peptide as a novel immune therapy in metastatic Renal Cell Carcinoma
Rahma, O. E., Ashtar, E., Ibrahim, R. A., Toubaji, A., Gause, B. L., Herrin, V. E., Linehan, W. M., Steinberg, S. M., Grollman, F., Grimes, G. J., et al. (2010) · Journal of Translational Medicine · doi:10.1186/1479-5876-8-8 · Cited by 41
Self-citation
BIALLELIC INACTIVATION OF THE VON HIPPEL-LINDAU TUMOR SUPPRESSOR GENE IN SPORADIC RENAL CELL CARCINOMA
HAMANO, K., Esumi, M., Igarashi, H., Chino, K., Mochida, J., ISHIDAand, H., & Okada, K. (2002) · The Journal of Urology · doi:10.1016/s0022-5347(01)69132-8 · Cited by 41
NK cells sense tumors, course of disease and treatments
Fregni, G., Perier, A., Avril, M., & Caignard, A. (2012) · OncoImmunology · doi:10.4161/onci.1.1.18312 · Cited by 41
Clear cell renal cell carcinoma with wild‐type von Hippel‐Lindau gene: a non‐existent or new tumour entity?
Batavia, A. A., Schraml, P., & Moch, H. (2018) · Histopathology · doi:10.1111/his.13749 · Cited by 42
Epididymal cystadenomas and epithelial tumourlets: effects of VHL deficiency on the human epididymis
Gläsker, S., Tran, M. G. B., Shively, S. B., Ikejiri, B. L., Lonser, R. R., Maxwell, P. H., Zhuang, Z., Oldfield, E., & Vortmeyer, A. (2006) · The Journal of Pathology · doi:10.1002/path.2029 · Cited by 41
Molecular alterations in sporadic breast cancer
Lerebours, F., & Lidereau, R. (2002) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(01)00191-3 · Cited by 41
DHPLC-based germline mutation screening in the analysis of the VHL tumor suppressor gene: usefulness and limitations
Klein, B., Weirich, G., & Brauch, H. B. (2001) · Human Genetics · doi:10.1007/s004390100500 · Cited by 41
Self-citation
Hypoxia-inducible factor 2α: a novel target in gliomas
Renfrow, J. J., Soike, M. H., Debinski, W., Ramkissoon, S. H., Mott, R. T., Frenkel, M. B., Sarkaria, J. N., Lesser, G. J., & Strowd, R. E. (2018) · Future Medicinal Chemistry · doi:10.4155/fmc-2018-0163 · Cited by 40
VHL tumor suppressor regulates Cl−/HCO3−exchange and Na+/H+exchange activities in renal carcinoma cells
Karumanchi, S. A., Jiang, L., Knebelmann, B., Stuart-Tilley, A. K., Alper, S. L., & Sukhatme, V. P. (2001) · Physiological Genomics · doi:10.1152/physiolgenomics.2001.5.3.119 · Cited by 40
Inhibition of Pax2 Transcription Activation with a Small Molecule that Targets the DNA Binding Domain
Grimley, E. C., Liao, C., Ranghini, E. J., Nikolovska‐Coleska, Z., & Dressler, G. R. (2017) · ACS Chemical Biology · doi:10.1021/acschembio.6b00782 · Cited by 40
Endoplasmic reticulum/cytosolic localization of von Hippel-Lindau gene products is mediated by a 64-amino acid region
Schoenfeld, A. R., Davidowitz, E. J., & Burk, R. D. (2001) · International Journal of Cancer · doi:10.1002/1097-0215(20010215)91:4 · Cited by 40
The Molecular Basis of Von Hippel-Lindau Disease
Iliopoulos, O., & Kaelin, W. G. (1997) · Molecular Medicine · doi:10.1007/bf03401807 · Cited by 40
Mechanisms of Disease: the role of heat-shock protein 90 in genitourinary malignancy
Lattouf, J., Srinivasan, R., Pinto, P. A., Linehan, W. M., & Neckers, L. Μ. (2006) · Nature Clinical Practice Urology · doi:10.1038/ncpuro0604 · Cited by 40
Self-citation
New HIF2α inhibitors: potential implications as therapeutics for advanced pheochromocytomas and paragangliomas
Toledo, R. A. (2017) · Endocrine Related Cancer · doi:10.1530/erc-16-0479 · Cited by 42
Extraneuraxial Hemangioblastoma: Clinicopathologic Features and Review of the Literature
Bisceglia, M., Muscarella, L. A., GALLIANI, C. A., Zidar, N., Ben‐Dor, D., Pasquinelli, G., la Torre, A., Sparaneo, A., Fanburg–Smith, J. C., Lamovec, J., et al. (2017) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000176 · Cited by 39
Clinicopathologic Significance of VHL Gene Alteration in Clear-Cell Renal Cell Carcinoma: An Updated Meta-Analysis and Review
Kim, H. S., Kim, J. H., Jang, H. J., Han, B., & Zang, D. Y. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19092529 · Cited by 39
Functional Subunits of Eukaryotic Chaperonin CCT/TRiC in Protein Folding
Kabir, M. A., Uddin, W., Narayanan, A., Reddy, P. K., Jairajpuri, M. A., Sherman, F., & Ahmad, Z. (2011) · Journal of Amino Acids · doi:10.4061/2011/843206 · Cited by 41
Familial Renal Cancer: Molecular Genetics and Surgical Management
Barrisford, G. W., Singer, E. A., Rosner, I. L., Linehan, W. M., & Bratslavsky, G. (2011) · International Journal of Surgical Oncology · doi:10.1155/2011/658767 · Cited by 40
Self-citation
Characterization of N-diethylnitrosamine-initiated and ferric nitrilotriacetate-promoted renal cell carcinoma experimental model and effect of a tamarind seed extract against acute nephrotoxicity and carcinogenesis
Vargas-Olvera, C. Y., Sánchez‐González, D. J., Solano, J. D., Aguilar-Alonso, F. A., Montalvo-Muñoz, F., Martínez‐Martínez, C. M., Medina‐Campos, O. N., & Ibarra‐Rubio, M. E. (2012) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-012-1373-0 · Cited by 39
Polyploidization and Losses of Chromosomes 1, 2, 6, 10,13, and 17 in Three Cases of Chromophobe Renal Cell Carcinomas
Gunawan, B., Bergmann, F., Braun, S., Hemmerlein, B., Ringert, R.-H., Jakse, G., & FÜZESI, L. (1999) · Cancer Genetics and Cytogenetics · doi:10.1016/s0165-4608(98)00185-x · Cited by 39
LINE-I element insertion at the t(11;22) translocation breakpoint of a desmoplastic small round cell tumor
Liu, J., Nau, M. M., Zucman‐Rossi, J., Powell, J. I., Allegra, C. J., & Wright, J. J. (1997) · Genes Chromosomes and Cancer · doi:10.1002/(sici)1098-2264(199703)18:3 · Cited by 43
The application of cytogenetics and fluorescence in situ hybridization to fine‐needle aspiration in the diagnosis and subclassification of renal neoplasms
Roh, M. H., Cin, P. D., Silverman, S. G., & Cibas, E. S. (2010) · Cancer Cytopathology · doi:10.1002/cncy.20077 · Cited by 38
Understanding the molecular genetics of renal cell neoplasia: implications for diagnosis, prognosis and therapy
Liang Cheng, C., Williamson, S. R., Zhang, S., MacLennan, G. T., Montironi, R., & Antonio Lopez-beltran, B. (2010) · Expert Review of Anticancer Therapy · doi:10.1586/era.10.72 · Cited by 38
lncRNA PVT1 in the Pathogenesis and Clinical Management of Renal Cell Carcinoma
Bohošová, J., Kubíčková, A., & Slabý, O. (2021) · Biomolecules · doi:10.3390/biom11050664 · Cited by 38
High frequency loss of heterozygosity in von Hippel-Lindau (VHL)-associated and sporadic pancreatic islet cell tumors: evidence for a stepwise mechanism for malignant conversion in VHL tumorigenesis.
Lott, S. T., Chandler, D. S., Curley, S. A., Foster, C. J., El‐Naggar, A. K., Frazier, M. L., Strong, L. C., Lovell, M., & Killary, A. M. (2002) · PubMed · Cited by 38
Fibroblast Growth Factor Receptor-Dependent and -Independent Paracrine Signaling by Sunitinib-Resistant Renal Cell Carcinoma
Tran, T. A. T., Leong, H. S., Pavía-Jiménez, A., Fedyshyn, S., Yang, J., Kucejová, B., Sivanand, S., Spence, P., Xie, X., Peña‐Llopis, S., et al. (2016) · Molecular and Cellular Biology · doi:10.1128/mcb.00189-16 · Cited by 38
Antitumor effect of parathyroid hormone-related protein neutralizing antibody in human renal cell carcinoma in vitro and in vivo
Talon, I., Lindner, V., Sourbier, C., Schordan, E., Rothhut, S., Barthelmebs, M., Lang, H., Helwig, J., & Massfelder, T. (2005) · Carcinogenesis · doi:10.1093/carcin/bgi203 · Cited by 38
Somatic mutations of von Hippel‐Lindau (VHL) tumor‐suppressor gene in european kidney cancers
Bailly, M., Bain, C., Favrot, M., & Öztürk, M. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910630510 · Cited by 38
Von Hippel-Lindau disease: gene to bedside
Sims, K. B. (2001) · Current Opinion in Neurology · doi:10.1097/00019052-200112000-00004 · Cited by 38
Hypoxia-associated autophagy flux dysregulation in human cancers
Fu, J., Lin, J., Dai, Z., Lin, B., & Zhang, J. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216823 · Cited by 37
Polycomb group genes are targets of aberrant DNA methylation in renal cell carcinoma
Avissar-Whiting, M., Koestler, D. C., Houseman, E. A., Christensen, B. C., Kelsey, K. T., & Marsit, C. J. (2011) · Epigenetics · doi:10.4161/epi.6.6.16158 · Cited by 37
Renal cancer-selective Englerin A induces multiple mechanisms of cell death and autophagy
Williams, R. T., Yu, A. L.-T., Diccianni, M. B., Theodorakis, E. A., & Batova, A. (2013) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-32-57 · Cited by 37
Are Pax proteins potential therapeutic targets in kidney disease and cancer?
Grimley, E. C., & Dressler, G. R. (2018) · Kidney International · doi:10.1016/j.kint.2018.01.025 · Cited by 38
Papillary Renal Cell Carcinoma: Analysis of Germline Mutations in the MET Proto-Oncogene in a Clinic-Based Population
Lindor, N. M., Dechet, C., Greene, M. H., Jenkins, R. B., Zincke, M. T., Weaver, A. L., Wilson, M., Zincke, H., & Liu, W. (2001) · Genetic Testing · doi:10.1089/109065701753145547 · Cited by 37
Genome-wide mapping of Hif-1α binding sites in zebrafish
Greenald, D., Jeyakani, J., Pelster, B., Sealy, I. M., Mathavan, S., & van Eeden, F. J. (2015) · BMC Genomics · doi:10.1186/s12864-015-2169-x · Cited by 42

Authors: Gnarra, J. R., Tory, K., Weng, Y., Schmidt, L., Wei, M. H., Li, H., Latif, F., Liu, S., Chen, F., Duh, F.-M., Lubensky, I., Duan, D. R., Florence, C., Pozzatti, R., Walther, M. M., Bander, N. H., Grossman, H. B., Brauch, H., Pomer, S., Brooks, J. D., Isaacs, W. B., Lerman, M. I., Zbar, B., & Linehan, W. M.
Affiliations: National Cancer Institute (US)
Frederick National Laboratory for Cancer Research (US)
National Institutes of Health (US)
Cornell University (US)
University of Michigan (US)
Technical University of Munich (DE)
Heidelberg University (DE)
Johns Hopkins University (US)
ORCID: Gnarra, J.R.
Schmidt, L.
Wei, M.H.
Lubensky, I.
Bander, N.H.
Brauch, H.
Brooks, J.D.
Isaacs, W.B.
Lerman, M.I.
Linehan, W.M.
Venue: Nature Genetics
Publisher: Springer Science and Business Media LLC
Published: 1994-05
Volume: 7
Issue: 1
Pages: 85-90
ISSN: 1061-4036 (ISSN-L)
1546-1718
DOI: 10.1038/ng0594-85
OpenAlex: W2010160635
Cited by: 1,730
References: 29
Citations by year: 2026: 17 · 2025: 25 · 2024: 30 · 2023: 38 · 2022: 38 · 2021: 45 · 2020: 56 · 2019: 47 · 2018: 45 · 2017: 42 · 2016: 57 · 2015: 35 · 2014: 70 · 2013: 66 · 2012: 62
FWCI: 61.77
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
Locations: Nature Genetics (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
Health Sciences › Medicine › Oncology › Ear and Head Tumors
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
Keywords: VHL gene, von Hippel-Lindau disease, renal carcinoma, clear cell renal cell carcinoma, loss of heterozygosity
MeSH terms: Base Sequence, Carcinoma, DNA Mutational Analysis, DNA, Neoplasm, von Hippel-Lindau Disease, Humans, Kidney Neoplasms, Molecular Sequence Data, Mutation, Organ Specificity, Polymorphism, Restriction Fragment Length, Genes, Tumor Suppressor, Neoplasms, Second Primary, Sequence Deletion, Adenocarcinoma, Clear Cell

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Mutations of the VHL tumour suppressor gene in renal carcinoma

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks